Phase III trials under way for Claritin metabolite

Schering-Plough Corp. has initiated its phase III trials for desloratadine, an active metabolite of Claritin(r). The patent rights to desloratadine were exclusively licensed to Schering-Plough in December 1997 by Sepracor, which conducted the pre-clinical trials showing potential for greater potency. As provided in the licensing agreement, Schering-Plough will market and manufacture desloratadine, with royalties paid to Sepracor.

COPYRIGHT 1998 Lebhar-Friedman, Inc.
COPYRIGHT 2000 Gale Group